Loading chart…
LIVE
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma.
Sun Pharma Advanced Research Company Limited (SPARC) is listed on the NSE in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. The SPARC share price is ₹191.26 (-1.48% today), with a market capitalisation of ₹62B and a price-to-earnings (P/E) ratio of 3.9. MarketRipple tracks the SPARC investment thesis, the ripple-chain impact of market events on Sun Pharma Advanced Research Company Limited, and the Healthcare sector outlook.
Open
₹194.56
High
₹201.59
Low
₹190.20
Prev. Close
₹194.13
52W High
₹289.00
52W Low
₹108.00
Day range
₹190.20–₹201.59
52-week range
₹108.00–₹289.00
Volume
837K
P/E
3.9
ROE
116.0%
D/E
0.42
Margin
83.0%
Sun Pharma Advanced Research Company Limited (NSE: SPARC) is currently trading at ₹191.26 (-1.48%).
Sun Pharma Advanced Research Company Limited's market capitalization is ₹62B.
Sun Pharma Advanced Research Company Limited's price-to-earnings (P/E) ratio is 3.9.
Sun Pharma Advanced Research Company Limited operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).